FATE THERAPEUTICS INC Restructuring Charges
FATE THERAPEUTICS INC (FATE) reported Restructuring Charges of $1.10 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2026-02-26
- FATE THERAPEUTICS INC restructuring charges for the quarter ending 2025-09-30 was $1.10M.
- FATE THERAPEUTICS INC restructuring charges for fiscal 2025 was $1.10M.
| Period end | Restructuring Charges 3 month | Restructuring Charges 12 month |
|---|---|---|
| 2025-12-31 | $1.10M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $1.10M 10-Q · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |